{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:00:42Z","timestamp":1792512042052,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Antipsychotic medications are commonly prescribed for older patients; however, documentation on their safety and efficacy in this population is limited. This study aimed to investigate and compare the effect of age on dose-adjusted serum concentrations of 6 commonly used antipsychotic medications in both sexes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients with serum concentration measurements of amisulpride, aripiprazole, clozapine, olanzapine, risperidone, and zuclopenthixol were retrospectively included from a therapeutic drug monitoring service. The primary outcome measure for each antipsychotic was the dose-adjusted serum concentration (C:D ratio), assessed across groups divided by sex and age (18\u201349 years, 50\u201374 years, and \u226575 years). The data were analyzed using linear mixed modeling with restricted maximum likelihood estimation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 19,926 patients (53% male) with 74,194 serum concentration measurements were included. For most antipsychotics, the C:D ratios increased significantly with age, with generally larger differences observed in females compared with males. The largest impact of age was observed for risperidone, where C:D ratios in the age groups 50\u201374 years and \u226575 years were 20% and 81% higher for males, respectively, compared with the reference group (18\u201349 years). For females, the C:D ratios were 28% and 92% higher, respectively, compared with females aged 18\u201349 years (all <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). The smallest impact of age was observed for aripiprazole, with no significant differences in C:D ratios across age groups for males. For females treated with aripiprazole, C:D ratios were 8% and 28% higher in the 50\u201374 and \u226575 years age groups, respectively, compared with females aged 18\u201349 years (both <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The age-dependent increase in dose-adjusted serum concentrations among males and females varied across different antipsychotics and was highest for risperidone. These findings emphasize the importance of proper monitoring of antipsychotic use in older adults.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001309","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T08:05:59Z","timestamp":1740470759000},"page":"662-668","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The Effect of Age on Antipsychotic Serum Concentration in Males and Females: A Study Based on Therapeutic Drug Monitoring Data From 19,926 Patients"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4138-9273","authenticated-orcid":false,"given":"Vigdis","family":"Solhaug","sequence":"first","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild Birkeland","family":"Waade","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Molden","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"},{"name":"Department of Pharmacy, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"St\u00f8rset","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"H\u00f8iseth","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"},{"name":"Department of Forensic Sciences, Oslo University Hospital, Oslo, Norway; and"},{"name":"Norwegian Center for Addiction Research, University of Oslo, Norway."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Tveito","sequence":"additional","affiliation":[{"name":"Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"R1-20250912","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.euroneuro.2017.07.001","article-title":"International trends in antipsychotic use: a study in 16 countries, 2005-2014","volume":"27","author":"H\u00e1lfd\u00e1narson","year":"2017","journal-title":"Eur Neuropsychopharmacol."},{"key":"R2-20250912","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archinternmed.2011.152","article-title":"Geriatric drug evaluation: where are we now and where should we be in the future?","volume":"171","author":"Cho","year":"2011","journal-title":"Arch Intern Med."},{"key":"R3-20250912","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.euroneuro.2018.09.007","article-title":"Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis","volume":"28","author":"Krause","year":"2018","journal-title":"Eur Neuropsychopharmacol."},{"key":"R4-20250912","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/bcp.14094","article-title":"Prescribing medicines to older people-how to consider the impact of ageing on human organ and body functions","volume":"86","author":"Drenth-van Maanen","year":"2020","journal-title":"Br J Clin Pharmacol."},{"key":"R5-20250912","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1023\/A:1015570104121","article-title":"Hospitalisations caused by adverse drug reactions (adr): a meta-analysis of observational studies","volume":"24","author":"Beijer","year":"2002","journal-title":"Pharm World Sci."},{"key":"R6-20250912","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JGP.0b013e318198776d","article-title":"Sensitivity of older patients to antipsychotic motor side effects: a pet study examining potential mechanisms","volume":"17","author":"Uchida","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"R7-20250912","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11920-009-0080-3","article-title":"Sensitivity to antipsychotic drugs in older adults","volume":"12","author":"Leon","year":"2010","journal-title":"Curr Psychiatry Rep."},{"key":"R8-20250912","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40263-024-01089-w","article-title":"Sex differences between female and male individuals in antipsychotic efficacy and adverse effects in the treatment of schizophrenia","volume":"38","author":"Galbally","year":"2024","journal-title":"CNS Drugs"},{"key":"R9-20250912","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2174\/138920011796504527","article-title":"Age-related changes in pharmacokinetics","volume":"12","author":"Shi","year":"2011","journal-title":"Curr Drug Metab."},{"key":"R10-20250912","doi-asserted-by":"crossref","first-page":"e63425","DOI":"10.7554\/eLife.63425","article-title":"Sex differences in biological aging with a focus on human studies","volume":"10","author":"H\u00e4gg","year":"2021","journal-title":"Elife"},{"key":"R11-20250912","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R12-20250912","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2125.2007.02852.x","article-title":"Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia","volume":"64","author":"Tang","year":"2007","journal-title":"Br J Clin Pharmacol."},{"key":"R13-20250912","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4088\/JCP.v60n0108","article-title":"Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics","volume":"60","author":"Lane","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R14-20250912","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00007691-200302000-00007","article-title":"Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication","volume":"25","author":"Gex-Fabry","year":"2003","journal-title":"Ther Drug Monit."},{"key":"R15-20250912","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/JCP.0000000000001618","article-title":"Effects of age, sex, and comedication on the plasma concentrations of olanzapine in Chinese patients with schizophrenia based on therapeutic drug monitoring data","volume":"42","author":"Ding","year":"2022","journal-title":"J Clin Psychopharmacol."},{"key":"R16-20250912","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881105053306","article-title":"Influence of age and gender on risperidone plasma concentrations","volume":"19","author":"Aichhorn","year":"2005","journal-title":"J Psychopharmacol."},{"key":"R17-20250912","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bcpt.12614","article-title":"Impact of ageing on serum concentrations of risperidone and its active metabolite in patients with known cyp2d6 genotype","volume":"119","author":"Molden","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R18-20250912","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/0269881108089806","article-title":"Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder","volume":"23","author":"M\u00fcller","year":"2009","journal-title":"J Psychopharmacol."},{"key":"R19-20250912","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00228-019-02768-0","article-title":"Impact of age and cyp2d6 genetics on exposure of aripiprazole and dehydroaripiprazole in patients using long-acting injectable versus oral formulation: relevance of poor and intermediate metabolizer status","volume":"76","author":"Tveito","year":"2020","journal-title":"Eur J Clin Pharmacol."},{"key":"R20-20250912","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00228-020-03002-y","article-title":"Impact of age and cyp2d6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients","volume":"77","author":"Tveito","year":"2021","journal-title":"Eur J Clin Pharmacol."},{"key":"R22-20250912","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/acps.12794","article-title":"Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine","volume":"136","author":"Castberg","year":"2017","journal-title":"Acta Psychiatr Scand."},{"key":"R23-20250912","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/FTD.0000000000000585","article-title":"A compilation of serum concentrations of 12 antipsychotic drugs in a therapeutic drug monitoring setting","volume":"41","author":"J\u00f6nsson","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R24-20250912","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1017\/S0033291721004591","article-title":"Antipsychotic medication for women with schizophrenia spectrum disorders","volume":"52","author":"Brand","year":"2022","journal-title":"Psychol Med."},{"key":"R25-20250912","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin Pharmacokinet."},{"key":"R26-20250912","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1517\/17425255.3.3.315","article-title":"The impact of advancing age on p-glycoprotein expression and activity: current knowledge and future directions","volume":"3","author":"Mangoni","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R27-20250912","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/hep.1840380424","article-title":"Sex is a major determinant of cyp3a4 expression in human liver","volume":"38","author":"Wolbold","year":"2003","journal-title":"Hepatology"},{"key":"R28-20250912","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/mol.109.056705","article-title":"Sex differences in the expression of hepatic drug metabolizing enzymes","volume":"76","author":"Waxman","year":"2009","journal-title":"Mol Pharmacol."},{"key":"R29-20250912","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00228-016-2178-y","article-title":"Impact of genetic and nongenetic factors on interindividual variability in 4\u03b2-hydroxycholesterol concentration","volume":"73","author":"Hole","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"key":"R30-20250912","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"Jama"},{"key":"R31-20250912","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia","volume":"146","author":"Gill","year":"2007","journal-title":"Ann Intern Med."},{"key":"R32-20250912","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/bmj.330.7497.922-c","article-title":"Fda warns about using antipsychotic drugs for dementia","volume":"330","author":"Lenzer","year":"2005","journal-title":"BMJ"},{"key":"R33-20250912","doi-asserted-by":"crossref","first-page":"371.e11","DOI":"10.1016\/j.jamda.2017.12.098","article-title":"Fall-risk-increasing drugs: a systematic review and meta-analysis: ii. Psychotropics","volume":"19","author":"Seppala","year":"2018","journal-title":"J Am Med Dir Assoc."},{"key":"R34-20250912","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1517\/17425255.2014.885504","article-title":"Clinically relevant interactions between newer antidepressants and second-generation antipsychotics","volume":"10","author":"Spina","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R36-20250912","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1080\/15622975.2024.2367138","article-title":"The european psychiatric association (epa) - early career psychiatrists committee survey on trainees' and early-career psychiatrists' attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment","volume":"25","author":"Schoretsanitis","year":"2024","journal-title":"World J Biol Psychiatry"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:02:19Z","timestamp":1757678539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001309","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"2024-10-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}